{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:00:40Z","timestamp":1770458440759,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2017005"],"award-info":[{"award-number":["2017005"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single\u2010center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorubicin+dexamethasone (RAD) or bortezomib+liposomal doxorubicin+dexamethasone (PAD) every 4\u00a0weeks, with subsequent autologous stem cell transplantation (ASCT) and maintenance therapy. We compared the efficacy, safety, patients\u2019 quality of life, and doctors\u2019 occupational stress between RAD and PAD induction in newly diagnosed MM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The complete response (CR) rate was comparable between the RAD and PAD groups after induction (30.8% vs. 32.0%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.92). Common adverse events, including infections, peripheral neuropathy, and gastrointestinal disturbances, were more frequent in the PAD group, while leukopenia and rashes were more common in the RAD group. Compared with PAD, RAD improved patients\u2019 quality of life more quickly and caused less occupational stress for doctors. However, only 31.6% of patients collected adequate CD34+ cells (\u22652\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup>\/kg) in the RAD group, which was significantly lower than that in the PAD group (95.5%, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001). The number of CD34+ cells collected was significantly higher in patients within three courses of RAD than in patients with four or five to six courses (14.18\u00a0\u00b1\u00a013.57 vs. 2.07\u00a0\u00b1\u00a02.42 vs. 1.51\u00a0\u00b1\u00a01.81\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup>\/kg, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.028). The median progression\u2010free survival and overall survival of the two groups were not reached by the end of follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to PAD, RAD induction had comparable efficacy and a significantly better safety profile, improved quality of life for patients, and reduced occupational stress for doctors. However, RAD induction may need to be limited to four cycles to avoid irreversible damage to hematopoietic stem cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>This study was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.chictr.org.cn\">www.chictr.org.cn<\/jats:ext-link> (ChiCTR1900021558).<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3762","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:01:10Z","timestamp":1612396870000},"page":"1656-1667","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of efficacy, safety, patients\u2019 quality of life, and doctors\u2019 occupational stress between lenalidomide\u2010based and bortezomib\u2010based induction in patients with newly diagnosed multiple myeloma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-7327","authenticated-orcid":false,"given":"Limei","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-4913","authenticated-orcid":false,"given":"Beihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifen","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waiyi","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2140-1845","authenticated-orcid":false,"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.498"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"issue":"2","key":"e_1_2_11_5_1","first-page":"167","article-title":"Safety of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer D","year":"2017","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2706"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0086"},{"key":"e_1_2_11_8_1","first-page":"6848902","article-title":"Efficacy and safety of novel agent\u2010based therapies for multiple myeloma: a meta\u2010analysis","volume":"2016","author":"Wang X","year":"2016","journal-title":"Biomed Res Int"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23587"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32125"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-004-0581-7"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4626"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.8"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.019"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.006"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01533.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0181-0"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15459"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9648"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013"},{"issue":"1","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13287-015-0033-1","article-title":"Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre\u2010transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte\u2010colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell'adulto Multiple Myeloma Working Party Study","volume":"6","author":"Musto P","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.175"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3762","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T04:53:49Z","timestamp":1692593629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/cam4.3762"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3762","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"2020-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}